Phase I/II Trial of MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

Phase I/II Trial of MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 19 May 2016 Protocol has been amended to change in treatment table, inclusion as well as exclusion criteria.
    • 18 Sep 2015 Planned primary completion date changed from 1 Oct 2020 to 1 Sep 2020 as reported by ClinicalTrials.gov.
    • 18 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top